Prostate Cancer Scientific Abstracts - S. Baba
Welcome to the Prostate Cancer Guide scientific abstracts, author section S. Baba.
This section is recommended for people who have a scientific interest in prostate cancer. It is recommended that people without prior knowledge of prostate cancer visit the more general areas of the site (Prostate Cancer Guide).
Selected S. Baba prostate cancer abstracts
Journal: British Journal of Urologyl
Pubmed ID: 6810984
Authors: Baba S, Janetschek G, Pollow K, Hahn K, Jaobi GH..Title: The effects of chlorotrianisene (Tace) of kinetics of 3H-testosterone metabolism in patients with carcinoma of the prostate.
Alterations in the metabolism of testosterone and plasma levels of testosterone,
luteinising hormone (LH), follicle stimulating hormone (FSH), prolactin and
oestradiol were studied in 6 patients with newly diagnosed prostatic carcinoma
before and during treatment with chlorotrianisene at a daily dosage of 48 mg for
14 days. Parameters of plasma kinetics were determined according to the single
injection technique and the 2-compartment model, and the plasma hormones by
radioimmunoassay. Chlorotrianisene altered neither plasma levels of
testosterone, gonadotrophins, prolactin and oestradiol, nor metabolic clearance
rate, production rate and other kinetic parameters of testosterone. Thus the
beneficial effects which have been reported previously cannot be explained by
suppression of peripheral testosterone metabolism.
Journal: Journal of Urology
Pubmed ID: 642094
Authors: Baba S, Murai M, Jitsukawa S, Hata M, Tazaki H.Title: Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men.
A decrease in the level of plasma testosterone and an increase in the level of plasma progesterone were noted after spironolactone had been administered for 20 days in 5 patients with prostatic carcinoma, as well as in 8 male dogs. Electron microscopic observation disclosed myelin-like bodies in the cytoplasm of Leydig and adrenocortical cells in dogs, contributing to a resolution of the mode of antiandrogenic action of spironolactone.